First patient receives experimental cell therapy for Tough-to-Treat leukemia
NCT ID NCT05739409
Summary
This was a very early, exploratory study to check the safety of a new type of cell therapy called LILRB4 STAR-T cells in adults with a specific form of leukemia that has not responded to other treatments. Only one patient was enrolled to receive the treatment after a short course of chemotherapy. The main goal was to see if the treatment was safe and tolerable, while also looking for early signs that it might help fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.